One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA

Documenti analoghi

• Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
  di: Ruoyang Jiao, et al.
  Pubblicazione: (2024)
• Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
  di: Gregor A. Maier, et al.
  Pubblicazione: (2026)
• Anti‐ VEGF monotherapy versus anti‐ VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta‐analysis
  di: Xiaofei Yang, et al.
  Pubblicazione: (2025)
• An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
  di: Geremia B. Bolli, et al.
  Pubblicazione: (2025)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)